April 28, 2021
Denka Company Limited

Denka Supplies COVID-19 Antigen Test Kits to Xtrava Health< SPERATM COVID-19 Ag Test >Denka Company Limited (headquarters: Chuo-ku, Tokyo; president: Toshio Imai; hereinafter,"Denka") announces that it will supply its QuickNavi™-COVID19 Ag COVID-19 antigen test kits
relabeled as SPERATM COVID-19 Ag Test as a manufacturer for the U.S.-based Xtrava Health(*1) per
Xtrava Health’s U.S. market specifications.
The United States (U.S.) is expanding COVID-19 testing in hospitals or clinics, nursing andeducational facilities and now into households under its emergency use authorization in order to stop
the spread of the disease. Given that testing demand is expected to further grow as a result of theincreasing scope of mass screenings and testing frequency, Denka has decided to supply Xtrava Healthwith its quick COVID-19 antigen test kits that can be used swiftly and easily.
On March 5, 2021, Xtrava Health was awarded a contract by the National Institutes of Health (NIH)
under the Rapid Acceleration of Diagnostics (RADxSM)(*2) initiative to expedite the launch ofSPERA™ COVID-19 antigen test. Xtrava Health is currently running the clinical trials to obtain FDA
EUA for point-of-care use, and launch targeted for later this year.
Denka and Xtrava Health will combine the Denka COVID-19 antigen test technology with the Xtrava
Health companion digital test platform(*3) that detects the results with a connected reader to enableimproved sensitivity, ease of use and result reporting for the over-the-counter (OTC) use.(*4)
Denka believes that measures to prevent infectious diseases are a part of its social responsibilities andit has strived to prevent the spread of infectious diseases through its work on both preventive anddiagnostic measures as the only company producing and selling various types of quick virus antigen
test kits and influenza vaccines, including test kits for the COVID-19 coronavirus. Going forward, it
will continue to contribute to the improvement of prevention and inspection systems in response to
demand from healthcare providers, and improve the quality of people ’lives. Through these efforts, itwill seek to create a company that is genuinely needed by society.

(*1)

Xtrava Health (headquarters: Santa Clara, California; CEO: Sameh Sarhan)
A manufacturer of medical devices established in 2014 to contribute to global healthcare throughcutting-edge
edge technologies, engaging in the development and supply of healthcare devices that allow
individuals to monitor their health conditions quickly and easily.
(*2)

Rapid Acceleration of Diagnostics (RADx SM) initiative
A research support initiative launched by the NIH to accelerate innovation in the development andcommercialization of technologies for accurate, fast and easy-to-use
easy
COVID-19
COVID
testing.
Xtrava Health is one of the 29 companies selected from a pool of over 700 RADx applicants. The
award of this contract followed months of diligence and vetting of Xtrava Health’s technology andscale-up plans by clinical, diagnostics industry, and academic experts including independent
evaluation and validation of the SPERA™ COVID
COVID-19 Ag Test’s analytical and clinical performanceby Emory University.
University
This Xtrava Health project has been funded in part by the NIH Rapid Acceleration of Diagnostics(RADxSM) initiative with U.S. federal funds from the National Institute of Biomedical Imaging andBioengineering, National Institutes of Health, Department of Health and Human Services, underContract No. 75N92021C00002.
(*3)

A connected quick antigen test kit reader

A reader developed by Xtrava Health Using LED light, it assesses positive/negative results of quick
antigen test kits inserted into the reader with an accuracy and sensitivity higher than visual inspection.
It can send results to the cloud or electronic medical records for storage through a smartphone while
also making it possible to understand the status of infection in specific areas by synchronizing thisdata with location information.
(*4)

Over-the-counter (OTC) medical market
A market of pharmaceutical products that may be purchased over the counter without prescriptions
from medical doctors.
About Denka
Denka is a chemical manufacturer headquartered in Chuo-ku,
ChuoTokyo. The company specializes indeveloping business activities on a global scale across a wide range of fields, from inorganic and organic
chemicals, to electronic materials and pharmaceuticals. Founded in 1915, Denka has steadily continued todevelop and manufacture products that contribute to the development of society by fully utilizing its uniqueconcepts and technological capabilities. Upholding its corporate slogan, “PossibilityPossibility of chemistry” thecompany and its president, Toshio Imai, are committed to contributing to the sound development of thesociety while sincerely tackling the challenges that the society is now confronting.
confronting[For Inquiries about This Press Release from Media]
Corporate Communications Dept. Tel : +81-3-5290-5511